While I'm not happy with having an average basis of $5.05 now, after adding another 5K shares during this latest sell-off (so collectively, 15K share position), everything I read about SGI-110 is very positive, indicates tremendous opportunity, etc. I don't typically (as in almost never) invest in such an early stage biotech company, but this company made the exception to my general rule on account of such an impressive (albeit early stage) pipeline coupled with a monster cash reserve and already one commercial product with a great revenue stream. I think the sell-off is way overdone, but since I'm in for the long haul.
Catalysts will come, share appreciation will follow, shareholders will be rewarded. Here are some upcoming events, per ASTX's website, to look forward to that may push the stock.
Scientific and Partnering Events
Astex Pharmaceuticals™ will be participating in the following scientific and partnering events. View a complete list of investor events.
Or view the events archive.
10-11 June 2013
Oxford Global: 14th Annual Drug Discovery Leaders Summit
13-16 June 2013
European Hematology Association (EHA)
20-22 June 2013
6th International Nasopharyngeal Carcinoma Symposium
23-26 June 2013
Frontiers in Medicinal Chemistry Symposium
San Francisco, CA
25-28 June 2013
Elsevier: 14th Tetrahedron Symposium
17-20 July 2013
8th World Congress of Melanoma
22-25 July 2013
23rd International Symposium: Synthesis in Organic Chemistry